Table 4.

Incremental economic analysis estimates (US$2019) for different immunization options for different policy options by World Bank Income Levels (2022–2035)

Vaccine policy	Base case paralytic cases	Policy paralytic cases	Cases prevented	Base case vaccine costs (millions)	Policy vaccine costs (millions)	Incremental financial costs* (millions)	Incremental net benefits* (INBs, millions)
Passive PAVD 40% effectiveness vs. no PAVD base case
LI	97,492	97,493	−1	4,920.9	4,920.9	0.0	0.0
LMI	169,377	169,234	143	11,041.7	11,045.4	3.7	−1.2
UMI	7,853	7,831	22	13,417.4	13,417.3	−0.1	2.6
HI	45	47	−2	18,925.7	18,927.1	1.3	−3.5
Total	274,767	274,605	162	48,305.6	48,310.6	4.9	−2.1
Active PAVD 90% effectiveness vs. no PAVD base case
LI	97,492	96,692	800	4,920.9	4,911.9	−9.0	15.6
LMI	169,377	168,592	785	11,041.7	11,021.8	−19.8	41.8
UMI	7,853	7,851	2	13,417.4	13,415.7	−1.7	2.2
HI	45	45	0	18,925.7	18,926.0	0.3	−0.3
Total	274,767	273,181	1,586	48,305.6	48,275.4	−30.3	59.3

Notes:

^*includes treatment costs of paralytic case, does not include PAVD policy related costs

Abbreviations:HI, high income; LI, low-income; LMI, lower middle-income; PAVD, polio antiviral drug; UMI, upper middle-income, US$2019, 2019 United States dollars